Atossa Genetics, The Breast Health Company™, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography. Atossa markets ForeCYTE Breast Health Test and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors. For more information visit the company’s Web site at www.atossagenetics.com
Let us hear your thoughts below: